原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展  

Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols

作　　者：刘贤国[1,2] 徐红玉 朱江 LIU Xianguo;XU Hongyu;ZHU Jiang(Thoracic Cancer Ward of Cancer Center,West China Hospital,Sichuan University,Chengdu 610044,China)

机构地区：[1]四川大学华西医院肿瘤中心胸部肿瘤病房,四川成都610044 [2]三六三医院肿瘤科,四川成都610041

出　　处：《陕西医学杂志》2023年第10期1438-1441,共4页Shaanxi Medical Journal

基　　金：四川省医学青年创新科研计划课题(Q20074)。

摘　　要：门静脉癌栓(PVTT)是原发性肝癌(HCC)常见并发症之一,严重影响患者生活质量和预后。PVTT形成的原因复杂,机制尚不完全清楚。目前,除传统手术治疗外,以经导管肝动脉化疗栓塞术(TACE)为主联合其他介入治疗手段如:射频消融、放射治疗、靶向药物、免疫治疗等联合应用可取得良好效果。现对原发性肝癌伴门静脉癌栓产生机制及TACE联合其他介入治疗方案的应用进展做一综述,以期对肝癌的临床诊疗工作提供帮助。Portal vein cancer thrombus(PVTT)is one of the common complications of primary liver cancer(HCC),which seriously affects the quality of life and prognosis of patients.The causes of PVTT formation are complex and the mechanism is not fully understood.At present,in addition to traditional surgical treatment,transcatheter hepatic arterial chemoembolization(TACE)combined with other interventional treatment methods such as radiofrequency ablation,radiotherapy,targeted drugs,immunotherapy and other combined applications can achieve good results.This article reviews the mediator of primary liver cancer with portal vein cancer and the application progress of TACE combined with other interventional programs,in order to provide help for the clinical diagnosis and treatment of liver cancer.

关 键 词：原发性肝癌 门静脉癌栓 导管肝动脉化疗栓塞术 介入治疗 放疗 

分 类 号：R735.7[医药卫生—肿瘤]